SuperworthIndivior Pharmaceuticals EPS INDV
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $2.78
- Latest quarter, Q2 FY26
- $0.98
- +600% on a year earlier
- Fiscal year 2025
- $1.63
- +2617% on the year before
Indivior Pharmaceuticals' earnings per share was $2.78 over the twelve months to Jun 30, 2026, up 227% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.98, up 600% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.63 | +2617% |
| FY2024 | $0.06 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.98 | +600% | $2.78 | |
| Q1 FY26 | $0.69 | +82% | $1.94 | |
| Q4 FY25 | $0.78 | +359% | $1.63 | |
| Q3 FY25 | $0.33 | +106% | $1.02 | |
| Q2 FY25 | $0.14 | n/a | $0.85 | |
| Q1 FY25 | $0.38 | −16% | −$0.01 | |
| Q4 FY24 | $0.17 | n/a | $0.06 | |
| Q3 FY24 | $0.16 | n/a | n/a | |
| Q2 FY24 | −$0.72 | n/a | n/a | |
| Q1 FY24 | $0.45 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Indivior Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| LQDALiquidia | $1.39 | |
| OGNOrganon | $0.77 | −71% a year |
| NRIXNurix Therapeutics | $2.31 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| Peer median | $1.18 |
Where Indivior Pharmaceuticals ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Indivior Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.